{"entity":{"id":"acib-funin-costa-rica","kind":"institution","name":"Agencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA (ACIB-FUNIN)","aka":["ACIB-FUNIN","ACIB","Agencia Costarricense de Investigaciones Biomédicas","Costa Rican Agency for Biomedical Research"],"tldr":"A Costa Rican research agency that has run the HPV vaccine trials in Guanacaste with the US National Cancer Institute, including the trial that found one dose of HPV vaccine as good as two.","summary":"The Agencia Costarricense de Investigaciones Biomédicas, linked with the Fundación INCIENSA, is the Costa Rican partner in the HPV vaccine studies run with the US National Cancer Institute's Division of Cancer Epidemiology and Genetics. ClinicalTrials.gov lists its site in Liberia, Guanacaste, for ESCUDDO (NCT03180034), the NCI-sponsored trial with the Gates Foundation as collaborator that randomised 20,330 girls aged 12 to 16 to one or two doses of a bivalent or nonavalent HPV vaccine and found one dose noninferior to two. Its researchers are authors of the Costa Rica Vaccine Trial of 7,466 women enrolled in 2004 and 2005, of PRIMAVERA in Guanacaste, and of PRISMA, a trial of single-dose vaccination in 4,925 women aged 18 to 30. Papers give its address as San José; the coordinates are an approximate point for Liberia, where the trials are run.\n\nThe Ministry of Health said in December 2023 that the agency had contributed two medical records staff to help bring the national cancer registry up to date.","asOf":"2026-11-11","links":[{"label":"ClinicalTrials.gov: ESCUDDO, NCT03180034 (site and sponsor)","url":"https://clinicaltrials.gov/study/NCT03180034"},{"label":"Kreimer et al., one HPV vaccine dose versus two (NEJM 2025)","url":"https://doi.org/10.1056/NEJMoa2506765"},{"label":"Ministerio de Salud: update of Registro Nacional de Tumores data (15 December 2023)","url":"https://www.ministeriodesalud.go.cr/index.php/prensa/60-noticias-2023/1739-salud-actualiza-datos-de-tumores-malignos-del-registro-nacional-de-tumores-en-pagina-web"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["hpv-bivalent-vaccine","gardasil-9"],"companies":[],"institutions":["nci","gates-foundation","costa-rica-ministry-of-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-kreimer-escuddo-one-dose-hpv-nejm-2025","paper-porras-costa-rica-vaccine-trial-11-years-lancet-oncol-2020","paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025"],"journals":[],"dependsOn":[],"notes":[],"city":"Liberia","country":"CR","lat":10.635,"lng":-85.438,"institutionType":"research-institute","programs":["Costa Rica HPV Vaccine Trial (CVT)","ESCUDDO single-dose HPV vaccine trial","PRIMAVERA immunobridging trial","PRISMA single-dose trial in women aged 18 to 30"]},"route":"/institutions/acib-funin-costa-rica/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/"},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/"}],"institution":[{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/"},{"id":"costa-rica-ministry-of-health","kind":"institution","name":"Ministerio de Salud, Costa Rica","route":"/institutions/costa-rica-ministry-of-health/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"paper":[{"id":"paper-porras-costa-rica-vaccine-trial-11-years-lancet-oncol-2020","kind":"paper","name":"Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial","route":"/key-papers/paper-porras-costa-rica-vaccine-trial-11-years-lancet-oncol-2020/"},{"id":"paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025","kind":"paper","name":"HPV 16 and 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9 to 14 years compared with three doses of quadrivalent vaccine in women aged 18 to 25 years in Costa Rica (PRIMAVERA)","route":"/key-papers/paper-cortes-primavera-single-dose-hpv-lancet-infect-dis-2025/"},{"id":"paper-kreimer-escuddo-one-dose-hpv-nejm-2025","kind":"paper","name":"Noninferiority of one HPV vaccine dose to two doses (ESCUDDO)","route":"/key-papers/paper-kreimer-escuddo-one-dose-hpv-nejm-2025/"}]}}